14 structural-engineering-"https:" "https:" "https:" "https:" "https:" "https:" "https:" "Dip" Fellowship positions at City of Hope
-
. Gu’s lab and research, please visit: https://gu-lab.net and https://www.cityofhope.org/Zhaohui-Gu As a successful candidate, you will: Design and execute experiments to understand the molecular
-
, shaping the future of medicine through cutting-edge research. A Postdoctoral Fellowship position is available in the RSP Lab led by Dr. Sklavenitis Pistofidis. The RSP Lab (https://rsplab.org ) leverages
-
Medicine, and member of the City of Hope Comprehensive Cancer. The Perry laboratory uses structural biology approaches, together with small molecule and fragment-based drug discovery, computer-aided drug
-
-life environmental exposures and the prenatal origins of childhood leukemia, for example in our ReCord Study (https://record.umn.edu ). Applicants are required to submit a CV accompanied by a cover
-
Fellowship position is available in the RSP Lab led by Dr. Sklavenitis Pistofidis. The RSP Lab (https://rsplab.org ) leverages advanced multi-omic technologies, coupled with experimental perturbations and
-
cancer. Work in the lab utilizes both genetically engineered mouse models and in vitro systems. A combination of state-of-the-art surgical, genetic, cellular, biochemical, imaging, and metabolic flux
-
: https://www.nathlab.org As a successful candidate, you will: Collaborate closely with experimental scientists, mathematicians, and medical oncologists/surgeons to plan, design, and execute computational
-
, Cancer Biology, Chromatin Regulation, Cancer Epigenetics, Epigenetics Regulation, Cancer Metabolism, Immunology, Drug Discovery, Development, and Structural Biology, with an emphasis on RNA epigenetics
-
Institute at City of Hope. You will work on projects related to the molecular mechanisms underlying the aging-related diabetes development using genetically engineered mouse models and multiple omics
-
antibody-based approach to intervene the malignancies 3) Identification of novel therapeutic target using high-throughput CRISPR genetic screen (e.g., metabolic pathway, mitochondria structure) in immune